CYTK
Cytokinetics Inc
About CYTK
Cytokinetics, Incorporated is a late-stage biopharmaceutical company. It is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases. It is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates are: omecamtiv mecarbil, a cardiac myosin activator for the treatment of heart failure with reduced ejection fraction (HFrEF); CK-136, a cardiac troponin activator for the treatment of heart failure and other diseases; reldesemtiv (CK-2127107), a fast skeletal muscle troponin activator (FSTA) for the treatment of people living with debilitating diseases and conditions associated with muscular weakness; aficamten (CK-274), a cardiac myosin inhibitor designed to reduce the hypercontractility that is associated with hypertrophic cardiomyopathy (HCM); and CK-3772271 (CK-271), a second novel cardiac myosin inhibitor.
Buy US stocks in Australia starting with CYTK. Open an account and start investing today!
$4.24B
-
0.00%
625.08K
$45.10
$43.38
$44.89
$55.80
$30.27
CYTK FAQs
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in CYTK
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
